The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine

Journal of Critical Care

Volumn 40, Issue , 2017, Pages 113-118

  Ghazi Suliman, Mohamed A ^a   Ogungbenro, Kayode ^b   Kosmidis, Christos ^a   Ashworth, Alan ^a   Barker, Julian ^a   Szabo Barnes, Anita ^a   Davies, Andrew ^a   Feddy, Lee ^a   Fedor, Igor ^a   Hayes, Tim ^a   Stirling, Sarah ^a   Malagon, Ignacio ^a  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

antiretrovirals; ARTs; ECMO; Extracorporeal membrane oxygenation; pharmacokinetics; PK; veno venous extracorporeal membrane oxygenation; VV ECMO

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPHOTERICIN B LIPID COMPLEX; CD4 ANTIGEN; CLARITHROMYCIN; COTRIMOXAZOLE; DARUNAVIR; DEXAMETHASONE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EPINEPHRINE; LAMIVUDINE; MEROPENEM; METRONIDAZOLE; OSELTAMIVIR; PIPERACILLIN PLUS TAZOBACTAM; RITONAVIR; TENOFOVIR; ZANAMIVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; ASPERGILLOSIS; BAYES THEOREM; CASE REPORT; CD4 LYMPHOCYTE COUNT; CYTOREDUCTIVE SURGERY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SUBSTITUTION; DYSPNEA; ENDOTRACHEAL INTUBATION; EXTRACORPOREAL OXYGENATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA A (H1N1); INTENSIVE CARE UNIT; MALE; MIDDLE AGED; NONHUMAN; OXYGEN CONSUMPTION; PAPILLOMA; POPULATION MODEL; POST HOC ANALYSIS; PROCESS MODEL; RESPIRATORY FAILURE; STRIDOR; TREATMENT RESPONSE; VENO VENOUS EXTRACORPOREAL MEMBRANE OXYGENATION; VIRUS LOAD; BLOOD; DOSE RESPONSE;

BAYES THEOREM; DARUNAVIR; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACORPOREAL MEMBRANE OXYGENATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; RITONAVIR; TENOFOVIR;

EID: 85020725127     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2017.03.010     Document Type: Article

References (20)

1. Terragni, P., Faggiano, C., Ranieri, V., Extracorporeal membrane oxygenation in adult patients with acute respiratory distress syndrome. Curr Opin Crit Care 20:1 (2014), 86–91.
2. Samalavicius, R., Serpytis, M., Ringaitiene, D., Grazulyte, D., Bertasiute, R., Rimkus, B., et al. Successful use of extracorporeal membrane oxygenation in a human immunodeficiency virus infected patient with severe acute respiratory distress syndrome. AIDS Res Ther, 11, 2014, 37, 10.1186/1742-6405-11-37.
3. De Rosa, F., Fanelli, V., Corcione, S., Urbino, R., Bonetto, C., Ricci, D., et al. Extra Corporeal Membrane Oxygenation (ECMO) in three HIV-positive patients with acute respiratory distress syndrome. BMC Anesthesiol, 14, 2014, 37, 10.1186/1471-2253-14-37.
4. Boucher, B., Wood, G., Swanson, J., Pharmacokinetic changes in critical illness. Crit Care Clin 22:2 (2006), 255–271 [vi].
5. Shekar, K., Fraser, J.F., Smith, M., Roberts, J., Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care, 27(6), 2012, 741.e9-18, 10.1016/j.jcrc.2012.02.013.
6. Izzedine, H., Launay-Vacher, V., Baumelou, A., Deray, G., An appraisal of antiretroviral drugs in hemodialysis. Kidney Int 60:3 (2001), 821–830.
7. Hsu, A., Granneman, G., Bertz, R., Ritonavir. Clin Pharmacokinet 35 (1998), 275–291.
8. Molto, J., Xinarianos, G., Miranda, C., Pushpakom, S., Cedeno, S., Clotet, B., et al. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients. Clin Pharmacokinet 52 (2013), 543–553.
9. Rittweger, M., Arastéh, K., Clinical pharmacokinetics of darunavir. Clin Pharmacokinet 46 (2007), 739–756.
10. Kearney, B.P., Flaherty, J.F., Shah, J., Tenofovir disoproxil fumarate. Clin Pharmacokinet 43 (2004), 595–612.
11. Johnson, M., Moore, K., Yuen, G., Bye, A., Pakes, G., Clinical pharmacokinetics of lamivudine. Clin Pharmacokinet 36 (1999), 41–66.
12. Moltó, J., Xinarianos, G., Miranda, C., Pushpakom, S., Cedeño, S., Clotet, B., et al. Simultaneous pharmacogenetics-based population pharmacokinetic analysis of darunavir and ritonavir in HIV-infected patients. Clin Pharmacokinet 52:7 (2013), 543–553, 10.1007/s40262-013-0057-6.
13. Baheti, G., Kiser, J., Havens, P., Fletcher, C., Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients. Antimicrob Agents Chemother 55:11 (2011), 5294–5299, 10.1128/AAC.05317-11.
14. Bazzoli, C., Bénech, H., Rey, E., Retout, S., Salmon, D., Duval, X., et al. Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients. Antimicrob Agents Chemother 55:7 (2011), 3423–3431, 10.1128/AAC.01487-10.
15. Giguère, P., La Porte, C., Zhang, G., Cameron, B., Pharmacokinetics of darunavir, etravirine and raltegravir in an HIV-infected patient on haemodialysis. AIDS 23:6 (2009), 740–742.
16. Joseph, A., Khoo, S., Value of therapeutic drug monitoring in the management of patients with HIV infection undergoing haemodialysis. Int J STD AIDS 15:1 (2004), 67–68.
17. Aarons, L., Population pharmacokinetics. Int J Clin Pharmacol Ther Toxicol 30 (1992), 520–522.
18. Aarons, L., Population pharmacokinetics: theory and practice. Br J Clin Pharmacol 32 (1991), 669–670.
19. Musuamba, F.T., Mourad, M., Haufroid, V., De Meyer, M., Capron, A., Delattre, I.K., et al. Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation. Br J Clin Pharmacol 75 (2013), 1277–1288.
20. Vikram, L., Singh, R., Sandeep, S., Tarun, J., Mohan, D., Population pharmacokinetics of antiretroviral agents: an overview. Int Res J Pharm 3:7 (2012), 75–85.